Unipharma.ch

LITAK® (cladribine, 2-chloro-2'-deoxyadenosine, 2-CdA) is a purine nucleoside.

LITAK® is approved for recurrent or refractory follicular and diffuse non-Hodgkin's lymphoma, recurrent or refractory chronic lymphocytic leukemia and recurrent or refractory lymphoplasmacytic lymphoma (Waldenström's macroglobulinemia) in Switzerland (country of origin) since 2000.

LITAK®  is also registered in more than 40 countries around the world. In Europe, LITAK® has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of indolent Non-Hodgkin's lymphoma.

LITAK®  was registered in April 2004 within the whole European Communitiy including Norway and Iceland for the indication hairy cell leukemia as first-line therapy.